Tag: CELLB9®
October 7, 2019
PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund
PreveCeutical Medical Inc. is pleased to announce that it has received a cash refund of $616,802 AUD from the Australian...
September 23, 2019
PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program
PreveCeutical Medical Inc. (CSE:PREV, OTCQB: PRVCF, FSE:18H), is pleased to provide an update on its dual gene therapy program. September 3, 2019
PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics
PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has recently reached a significant...
March 25, 2019
PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.
PreveCeutical Medical Inc. (CSE:PREV, OTC:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), announces that it has obtained a default judgement against each... March 11, 2019
PreveCeutical Announces Preliminary Screening Results of Peptides Derived From Blue Scorpion Venom in a Cell-Based Brain Cancer Model
PreveCeutical Medical Inc. (CSE:PREV) (OTC:PRVCF) (FSE:18H) (the "Company" or "PreveCeutical"), is pleased to announce positive results from the preliminary screening of key... February 13, 2019
PreveCeutical Announces Appointment of Dr. Makarand Jawadekar as President
PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the "Company" or "PreveCeutical") is pleased to announce the appointment of Dr. Makarand (Mak)... February 12, 2019